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GEN (HLA) DOES NOT COMPROMISE OUTCOMES IN ADULTS UNDERGO-
ING MATCHED UNRELATED ALLOGENEIC BONE MARROW
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HLA allelemismatchingmay be associated with inferior outcomes
in unrelated stem cell transplantation. Since July 2005, our trans-
plant unit performed 4-digit (allele level) HLA Class-I typing for
all unrelated donors from National Marrow Donor Program and
2-digit Class I typing was on all others. All donors had four-digit
Class-II typing. We reviewed all patients who received matched un-
related transplants (HLA-A, B, C, DR, and DQ) between July 2005
and February 2009. We compared overall survival and cumulative
incidences of relapse, acute and chronic graft versus host disease
(aGvHD, cGvHD) between the 4- and the 2-digit typing cohorts.
Themean age is 44.9 yrs for the 86 consecutive pts (17 and 69 respec-
tively). Most pts (61/86) have acute myeloid/lymphoid Leukemia or
myelodysplastic syndrome. Conditioning regimens included: BUCY
(Busulfan 12.8 mg/kg, Cyclophosphamide 120 mg/kg, 5 pts), CY-
TBI (Cy 120 mg/kg, Total Body Irradiation 12 Grays, 21 pts),
Flu-Bu2 (Fludarabine 120 mg/m2, Bu 6.4 mg/kg, TBI 200 cGy, 38
pts), Flu-Bu4 (Flu 200 mg/m2, Bu 12.8 mg/kg, TBI 400 cGy, 19
pts) and Flu-Cy (Flu 120 mg/m2, Cy 40 mg/kg, 3 pts). Most grafts
are peripherally collected (68/86 pt) and most (63/86 pts) received
Alemtuzumab/CyA (Alemtuzumab 30 mg, Cyclosporine 5 mg/kg/
d) for GvHD prophylaxis. There are no statistically significant dif-
ferences between the baseline characteristics of the two groups
(age, sex, graft source, diagnosis, preparative regimen, GvHD pro-
phylaxis and CMV seropositivity). The median follow up is 25.3
months. Forty-two deaths occurred in both groups. The overall sur-
vival between the two groups is not statistically different (log rank
test, p5 0.58). There were 13 relapses with no statistically signifi-
cant difference in the cumulative rate of relapse between the two
groups, log-rank test p value5 0.91. Grade 2-4 aGvHD is seen in
52 pts and the cumulative rates are not different between the groups,
log-rank P value5 0.85. Thirty-three pts experienced limited or ex-
tensive cGvHD with no difference in the cumulative rates, log-rank
P value5 0.81. In a Cox model of overall survival using age, diagno-
sis, CMV seropositivity, GvHD prophylaxis, Conditioning regimen
and the level of matching; only diagnosis andCMV seropositivity are
statistically significant prognostic factors. In this single institution
retrospective study, 2-digit typing of HLA class-I is not associated
with inferior outcomes in matched unrelated transplantation.166
IS HLA MATCHING BY SBT A NECESSITY FOR BMT?
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burg, FL
Hematopoietic stem cell transplantation (HSCT) outcome has
improved dramatically since the introduction of allele level HLA
typing. Currently, HLA laboratories are using three different tech-
nologies for allele level matching, PCR amplification with se-
quence-specific primers (PCR-SSP), polymerase chain reaction-
sequence-specific oligonucleotide probes (SSOP), and sequence-
based typing (SBT). However, it is important to emphasize that
SBT is the only HLA typing method so far that allows scrutiny of ev-
ery nucleotide in the HLA gene sequence, therefore, it allows us to
recognize new alleles and potential gene mutations that would en-
sure allele level typing to be as good as claimed.
HLA high resolution typing was performed by SBT using Pro-
trans sequencing kits. Patient DNA samples were first PCR ampli-
fied by group-specific primer mixes to separate two HLA alleles.
The PCR products were then cycle-sequenced and processed on
an ABI 3100 genetic analyzer. Sequencing data were further analyzed
with the Assign 3.5 +HLA analysis software.
Our SBT data showed that the occurrence of new sequences in pa-
tients and donors is not negligible. We found it to be 3% in our local
ethnically diverse population, where a few patients even had two novel
sequences. Family analysis of sequencing data revealed that some se-
quence changes are actually HLA gene mutations that occur only inthe patient and are not found in the parents or siblings sharing the
same haplotype. By comparing patient peripheral blood samples with
buccal swabs, we confirmed that HLA gene mutations also occurred
in patient somatic cells. Had we used PCR-SSP or PCR-SSOP for
HLA typing these new alleles or mutations would have been missed.
We argue that spontaneous HLA gene mutations found in leuke-
mia or immunodeficiency patients that are not inherited fromparents
should not be reported as new alleles, unless the gene is known to be
passed on to the next generation that is healthy, or carried by at least
two normal individuals. If every mutation were reported as a new al-
lele, the already long lists of alleles would continue to increase, and
unnecessarily slow down the HLA matching process.
We speculate that HLA gene mutations might affect immune sur-
veillance and impact disease severity, because our patients with these
mutations had poor prognosis. Further study is required to clarify
the significance of HLA gene mutations.IMMUNE RECONSTITUTION
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FLT-3 LIGAND AND ANDROGEN WITHDRAWAL ENHANCE IMMUNE RE-
CONSTITUTION AFTER HSCT
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Impaired thymopoiesis contributes to immune deficiency following
HSCT.Clinical data suggest that thymic insufficiencymay contribute
to graft-versus-host disease and infectious clearance. We have previ-
ously shown that androgen withdrawal enhances thymus renewal by
thymic epithelial cell (TEC) proliferation, increased entry of thymic
progenitors and accelerated thymocyte development.Wenowdemon-
strate that FMS-like tyrosine kinase 3 (Flt-3) enhances thymopoiesis in
conjunction with androgen blockade. Flt-3 increases stem cell number
(LSK, Lineage- Sca-1+ cKit+), B cell precursors (Lineage- Sca-1 + IL-
7ra+), andT cell directed stemcells (Lineage- Sca-1+ cKit+CCR9+) in
the marrow of older mice without altering thymic function. Immature
granulocyte and dendritic cell precursors were also enriched in the
marrow. In contrast, in young mice, Flt-3 increased the emigration
of stem cells without altering the distribution of marrow cell popula-
tions. To test the effect of the Flt-3-treated marrow on thymic recon-
stitution, aged mice were pre-treated with lupron or saline and
conditioned with 900 cGy radiation. One million congenic T-cell de-
pleted marrow cells were adoptively transferred from Flt-3 treated or
saline treated donors. Flt-3-treated marrow in combination with lu-
pron led to themost rapid thymic reconstitution, nearly doubling total
congenic thymocytes by 5weeks post-transplant.Thymic subsetswere
increased including: CD4 single positive (2.67x), CD8 single positive
(2.69 x), double positive (1.92x), and double negative subsets (1.59x)
compared to saline-treatedmarrowand recipient controls.Thymocyte
subsets and total numbers were significantly greater in lupron-treated
hosts receiving Flt-3-treated marrow than in lupron-treated hosts re-
ceiving saline-treatedmarrow. Incontrast,Flt-3-treatedmarrowtrans-
ferred in the absence of lupron did not increase thymopoiesis. These
data suggest that: T cell directed precursor number and precursor en-
trymaybecritical points of thymic regulationpost-HSCT.Byenhanc-
ing TEC proliferation, T precursor emigration, and thymocyte
maturation via androgen withdrawal with lupron, it appears that pre-
cursor numberbecomes limiting. Flt-3 increasesTdirectedprecursors
in the marrow thereby further enhancing thymic recovery. These data
may present a clinical opportunity to improve thymic renewal follow-
ing stem cell transplantation by Flt-3 treatment of donors and andro-
gen withdrawal in hosts.168
IMMUNE RECONSTITUTION FOLLOWING REDUCED INTENSITY CONDI-
TIONING WITH CAMPATH-1H VERSUS TOTAL LYMPHOID IRRADIA-
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